Michael Butterworth Leicester Cancer Research Center University of Leicester Biography Publications Institution JoVE Articles Michael Butterworth has not added a biography. If you are Michael Butterworth and would like to personalize this page please email our Author Liaison for assistance. Publications Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis Neoplasia (New York, N.Y.). May, 2013 | Pubmed ID: 23633928 Role of NOXA and Its Ubiquitination in Proteasome Inhibitor-induced Apoptosis in Chronic Lymphocytic Leukemia Cells Haematologica. Sep, 2010 | Pubmed ID: 20378569 The Fate of Benzene-oxide Chemico-biological Interactions. Mar, 2010 | Pubmed ID: 20036650 Reconstitution of the Death-inducing Signaling Complex Reveals a Substrate Switch That Determines CD95-mediated Death or Survival Molecular Cell. Aug, 2009 | Pubmed ID: 19683492 The E3 Ubiquitin Ligase CIAP1 Binds and Ubiquitinates Caspase-3 and -7 Via Unique Mechanisms at Distinct Steps in Their Processing The Journal of Biological Chemistry. May, 2009 | Pubmed ID: 19258326 Concurrent Up-regulation of BCL-XL and BCL2A1 Induces Approximately 1000-fold Resistance to ABT-737 in Chronic Lymphocytic Leukemia Blood. Apr, 2009 | Pubmed ID: 19008458 Death Receptor-induced Apoptosis Reveals a Novel Interplay Between the Chromosomal Passenger Complex and CENP-C During Interphase Molecular Biology of the Cell. Apr, 2007 | Pubmed ID: 17287400 Attivazione Di Caspase Inibisce La Funzione Del Proteasoma Durante Il Apoptosis Molecular Cell. Apr, 2004 | Pubmed ID: 15068805 Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-apoptosis Protein The Journal of Biological Chemistry. Mar, 2002 | Pubmed ID: 11801595 Recruitment, Activation and Retention of Caspases-9 and -3 by Apaf-1 Apoptosome and Associated XIAP Complexes The EMBO Journal. Mar, 2001 | Pubmed ID: 11230124 Espianti tumorali derivati dal paziente come piattaforma preclinica "live" per prevedere la resistenza ai farmaci nei pazienti Giuditta Viticchié1, Ian Powley1, Constantinos Demetriou1, James Cooper1, Michael Butterworth1, Meeta Patel1, Naila Abid1, Gareth Miles1, Lynne Howells1, Howard Pringle1, Marion MacFarlane2, Catrin Pritchard1 1Leicester Cancer Research Center, University of Leicester, 2MRC Toxicology Unit JoVE 62130 Ricerca sul cancro
Espianti tumorali derivati dal paziente come piattaforma preclinica "live" per prevedere la resistenza ai farmaci nei pazienti Giuditta Viticchié1, Ian Powley1, Constantinos Demetriou1, James Cooper1, Michael Butterworth1, Meeta Patel1, Naila Abid1, Gareth Miles1, Lynne Howells1, Howard Pringle1, Marion MacFarlane2, Catrin Pritchard1 1Leicester Cancer Research Center, University of Leicester, 2MRC Toxicology Unit JoVE 62130 Ricerca sul cancro